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Abstract
Background: Mitochondrial DNA (mtDNA) is a critical activator of inflammation and the innate immune system. However,
mtDNA level has not been tested for its role as a biomarker in the intensive care unit (ICU). We hypothesized that circulating
cell-free mtDNA levels would be associated with mortality and improve risk prediction in ICU patients.
Methods and Findings: Analyses of mtDNA levels were performed on blood samples obtained from two prospective
observational cohort studies of ICU patients (the Brigham and Women’s Hospital Registry of Critical Illness [BWH RoCI, n= 200]
and Molecular Epidemiology of Acute Respiratory Distress Syndrome [ME ARDS, n= 243]). mtDNA levels in plasma were
assessed by measuring the copy number of the NADH dehydrogenase 1 gene using quantitative real-time PCR. Medical ICU
patients with an elevated mtDNA level ($3,200 copies/ml plasma) had increased odds of dying within 28 d of ICU admission in
both the BWH RoCI (odds ratio [OR] 7.5, 95% CI 3.6–15.8, p= 161027) and ME ARDS (OR 8.4, 95% CI 2.9–24.2, p= 961025)
cohorts, while no evidence for association was noted in non-medical ICU patients. The addition of an elevated mtDNA level
improved the net reclassification index (NRI) of 28-d mortality among medical ICU patients when added to clinical models in
both the BWH RoCI (NRI 79%, standard error 14%, p,161024) and ME ARDS (NRI 55%, standard error 20%, p=0.007) cohorts.
In the BWH RoCI cohort, those with an elevated mtDNA level had an increased risk of death, even in analyses limited to
patients with sepsis or acute respiratory distress syndrome. Study limitations include the lack of data elucidating the concise
pathological roles of mtDNA in the patients, and the limited numbers of measurements for some of biomarkers.
Conclusions: Increased mtDNA levels are associated with ICU mortality, and inclusion of mtDNA level improves risk prediction
in medical ICU patients. Our data suggest that mtDNA could serve as a viable plasma biomarker in medical ICU patients.
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Introduction
Multidimensional scoring systems based on commonly measured
clinical and physiologic parameters help to improve the prognos-
tication of patients admitted to intensive care units (ICUs) [1].
Despite the improvement in prognostication there is a need to
develop biomarkers that can help clinicians to further improve risk
prediction for patients in the ICU [2]. While many biomarkers
(.170) have been evaluated in various ICU subpopulations, few
have been tested in large populations, or add substantially to the
predictive value of multidimensional scoring systems [1]. Only a
small number of biomarkers reflecting the severity of critical illness
are commonly measured in clinical practice (e.g., lactate and
procalcitonin) [3,4]. Accumulating evidence suggests that cellular
mitochondrial DNA (mtDNA) levels are decreased [5,6] and
circulating cell-free mtDNA levels are increased in response to
stimuli such as trauma [7] and microbial infection [8–10].
Moreover, mtDNA acts as a damage-associated molecular pattern
[11] that can drive molecular processes, leading to inflammatory
responses and organ injuries [7,10,12,13]. Based on these findings
we hypothesized that circulating cell-free mtDNA levels would be
associated with mortality and would improve risk prediction in ICU
patients. The objective of this study was to test whether measuring
circulating cell-free mtDNA is useful as a biomarker in the ICU. To
our knowledge this is the first study to provide replicated evidence
that plasma mtDNA levels both are associated with mortality and
improve risk prediction in the field of critical care illness.
Methods
The protocols for patient recruitment and data collection for the
two patient cohorts, the Brigham and Women’s Hospital Registry
of Critical Illness (BWH RoCI, primary patient cohort) and the
Molecular Epidemiology of Acute Respiratory Distress Syndrome
(ME ARDS, replication cohort), have been described previously
[14–16] and are discussed in detail in Text S1 in Supporting
Information S1. In brief, from 24 July 2008 to 14 June 2011, 200
patients were prospectively recruited into the BWH RoCI study
from the Brigham and Women’s Hospital medical intensive care
unit (MICU), for whom clinical phenotype data, including
mortality, and blood plasma samples were subsequently collected.
Acute kidney injury was defined as a $0.5 mg/dl increase in
serum creatinine [17]. Presence of respiratory, heart, and liver
failure were defined by admitting physician report. For replication,
we selected 243 patients from the ME ARDS study, which
recruited patients from ICUs at Massachusetts General Hospital
from 10 November 2002 to 16 June 2010 and at Beth Israel
Deaconess Medical Center from 1 February 2007 to 24 April
2010, for whom both 28-d mortality data and a blood plasma
sample had been collected. In addition to baseline demographic
data, assessments of sepsis and acute respiratory distress syndrome
(ARDS) were performed, and Acute Physiology and Chronic
Health Evaluation (APACHE) II scores were measured [18–20].
28-d mortality [21] (in both cohorts) and in-hospital mortality (in
the BWH RoCI cohort) were ascertained from patient medical
records, and long-term mortality was assessed in the BWH RoCI
cohort by linking the cohort to the US Social Security
Administration’s Death Master File [22]. Written informed
consent and institutional review board approval were obtained.
Preparation and Quantification of Plasma DNA
In the BWH RoCI study, blood samples were drawn and
transferred into blood collection tubes within 24 h of study inclusion,
and processed within 2 h after venipuncture [14]. In the ME ARDS
study, blood samples were drawn and transferred into blood collection
tubes within 48 h after the establishment of a diagnosis [23].
DNA isolation from plasma. Plasma used in this study (from
both RoCI and ME ARDS) was collected in EDTA-coated blood
collection tubes. The plasma samples were stored at 280uC. DNA
was isolated from plasma using the DNeasy Blood and Tissue Kit
(#69504; Qiagen), according to the manufacture’s manual [12].
Samples were thawed on ice and were then mixed briefly by vortex.
The 100 ml of plasma was mixed with 100 ml of PBS, followed by
brief vortex. The diluted plasma was centrifuged at 700g at 4uC for
5 min, and the supernatant (190 ml) was carefully saved by avoiding
touching any pellets and the bottom of the tubes with pipette tips.
The obtained supernatant was further centrifuged at 18,000g at 4uC
for 15 min, and the resulting supernatant (170 ml) was carefully
saved. Contamination of cells, cell debris, or pellets into supernatant
might lead to a significant change of the results. The obtained
supernatant was processed for DNA isolation. In brief, we incubated
plasma samples with lysis buffer (included in the kit) and proteinase
K at 56uC for 15 min. At the final step of DNA isolation, DNA was
eluted in 200 ml of elution buffer (included in the kit). For the
quantitative real-time polymerase chain reaction (qPCR) assay, the
DNA solution was further diluted 10 times with nuclease-free
deionized, distilled H2O.
Primers and qPCR. DNA level in diluted samples was
measured by SYBR Green dye-based qPCR assay using a PRISM
7300 sequence detection system (Applied Biosystems). The primer
sequences were as follows: human NADH dehydrogenase 1 gene
(mtDNA): forward 59-ATACCCATGGCCAACCTCCT-39, reverse
59-GGGCCTTTGCGTAGTTGTAT-39 [7,24]; human b-globin
(nuclear DNA): forward 59-GTGCACCTGACTCCTGAGGAGA-
39, reverse 59-CCTTGATACCAACCTGCCCAG-39 [25]; bacterial
16S ribosomal RNA: forward 59- CGTCAGCTCGTGTTGT-
GAAA-39, reverse 59-GGCAGTCTCCTTGAGTTCC-39 [7]. Plas-
mid DNA with complementary DNA sequences for human mtDNA
was obtained from ORIGENE (SC101172), and plasmid DNA with
complementary DNA sequences for human nuclear DNA was
obtained from Sino Biological. Concentrations were converted to
copy number using the formula; mol/gram6molecules/mol=mole-
cules/gram, via a DNA copy number calculator (http://cels.uri.edu/
gsc/cndna.html; University of Rhode Island Genomics and Sequenc-
ing Center) [26,27]. DNA solutions were diluted in 10-fold serial
dilutions and used as standards.
The thermal profile for detecting mtDNA was carried out as
follows: an initiation step for 2 min at 50uC is followed by a first
denaturation step for 10 min at 95uC and a further step consisting
of 40 cycles for 15 s at 95uC and for 1 min at 60uC. A
representative standard curve, dissociation curve, and amplifica-
tion plot are shown in Figure 1.
All samples were analyzed in duplicate, and a no-template
control was included in every analysis. mtDNA levels in all of the
plasma analyses were expressed in copies per microliter of plasma
based on the following calculation [28]:
c~Q|VDNA=VPCR|1=Vext ð1Þ
where c is the concentration of DNA in plasma (copies/microliter
plasma); Q is the quantity (copies) of DNA determined by the
sequence detector in a PCR; VDNA is the total volume of plasma
DNA solution obtained after extraction, typically 200 ml per
extraction; VPCR is the volume of plasma DNA solution used for
PCR, typically 5 ml of ten times diluted plasma DNA solution; and
Vext is the volume of plasma extracted, typically 50–100 ml.
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The specificity of mtDNA primers was examined using bacterial
DNA (Text S2 in Supporting Information S1; Figure S1) and by
BLAST search (Text S3 and Tables S1 and S2 in Supporting
Information S1).
Procalcitonin Measurement
Plasma level of procalcitonin was measured using the Procalci-
tonin Human ELISA (Enzyme-Linked Immunosorbent Assay) Kit
(ab100630; Abcam).
Statistical Analysis
mtDNA level was assessed as both a continuous and a binary
variable, where indicated. Because mtDNA levels were non-
normally distributed, continuous levels from the BWH RoCI
cohort were assessed after log10 transformation and dichotomized
using visual inspection and iterative methods (using c-statistics)
[29] to select the level of mtDNA that maximized the area under
the curve for the prediction of 28-d mortality (mtDNA $3,200
copies/ml versus ,3,200 copies/ml). This level was then replicated
in the ME ARDS cohort. Survival was assessed as both a binary
and a time-dependent variable. Bivariate analyses were conducted
with Fisher’s exact tests (for categorical variables) and Wilcoxon
rank-sum tests (for continuous variables). Both bivariate and
multivariate logistic regression models were used in association
analyses. Survival analyses were performed using log-rank and
Cox-proportional hazards models.
To assess the value of mtDNA level in risk prediction, we
compared bivariate and multivariate models with and without
mtDNA level using the net reclassification improvement approach
Figure 1. Representative standard curve, amplification plot, and dissociation curve, and amplification plot from the patients’
samples. (A) NADH dehydrogenase 1 complementary DNA was serially (1:10) diluted to prepare a series of calibrators (mtDNA standard) with known
DNA copy number. The assay was linear over the range (8.48–848000 copies) of DNA copy numbers (R2 = 0.997866). (B) The amplification plot (DRn
versus cycle [log] view) shows no irregular amplification for the standard diluents (848,000, 84,800, 8,480, 848, 84.8, 8.48). (C) The dissociation curve
shows a single melting temperature of the specific products generated with standard template. Also, there is no melting temperature observed in the
no-template control wells (blank). These dissociation curves indicate that the reactions are free of primer-dimer or any other spurious products. (D)
Similar amplification plots were observed after qPCR using patients’ samples. The amplification curves generated from human samples were
paralleled with the curves from standards and were in the range of amplification plots for standard diluents.
doi:10.1371/journal.pmed.1001577.g001
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[30] (using risk categories in increments of 10% from 0% to
100%). In contrast to c-statistics, the net reclassification index
(NRI) may have unique value in assessing the ability of a
biomarker to improve risk prediction when groups can be split up
into risk strata. All analyses were performed using Statistical
Analysis Software version 9.2 (SAS Institute). Analyses comparing
c-statistics and net reclassification were performed using rocplus
[31]. p,0.05 was considered statistically significant.
Results
Baseline Characteristics
Baseline characteristics of ICU patients included in the BWH
RoCI (n=200) and the ME ARDS (n=243) cohorts are presented
in Table 1. While the BWH RoCI cohort was entirely composed
of MICU patients, the ME ARDS cohort included patients from
different ICU types. Patients in both studies were more likely to be
white, to be female, and to carry a diagnosis of sepsis; however,
these covariates were even more prevalent among patients in the
ME ARDS cohort. A diagnosis of ARDS was more common in
ME ARDS patients than in BWH RoCI patients. Age, APACHE
II scores, and mtDNA levels were similar in both studies. Of note,
only one patient in either study (in ME ARDS) received activated
protein C during their stay in the ICU.
The additional analysis of patient characteristics is shown in
Text S4 in Supporting Information S1.
Of the 200 patients in the BWH RoCI study, 60 (30%) died
within 28 d of MICU admission, and 51 (25%) died in the
Table 1. Baseline characteristics of the ICU patients.
Category Variable Number (Percent) or Median (Interquartile Range)
BWH RoCI (n=200) ME ARDS (n=243)
Demographic parameters Age (years) 60 (46–69) 59 (45–71)
Gender (female) 117 (59%) 158 (65%)
Race/ethnicity
White 155 (78%) 219 (90%)
African-American 26 (13%) 5 (2%)
Hispanic 13 (7%) 14 (6%)
Asian or Pacific Islander 6 (3%) 5 (2%)
Clinical parameters ICU type
Medical 200 (100%) 126 (52%)
Cardiac 26 (11%)
Surgical 82 (34%)
Trauma 7 (3%)
Neurological 2 (1%)
Cancer
Any 89 (45%) —
Metastatic solid tumor — 4 (2%)a
APACHE II score 24 (18–30) 22 (18–26)
Acute kidney injuryb 57 (29%)a —
Need for mechanical ventilation 90 (45%)a —
Heart failurec 17 (9%)a —
Liver failurec 20 (10%)a 10 (4%)a
Vasopressor use 71 (36%)a —
Sepsis 124 (62%) 187 (77%)
ARDS 30 (15%) 104 (43%)a
Mortality data 28-d mortality 60 (30%) 40 (16%)
In-hospital morality 51 (26%) —
Overall mortality 93 (47%) —
Peripheral blood biomarkers of
ICU mortality
mtDNA (copies/ml)d 3,379 (1,123–12,227) 3,544 (1,130–10,557)
Procalcitonin (mg/l) 3.6 (0.9–12.1)a —
Lactate (mg/dl) 1.9 (1.2–4.0)a —
aData missing in BWH RoCI cohort for liver failure in one patient (0.5%), for acute kidney injury, need for mechanical ventilation, and heart failure in two patients (1%),
for vasopressor use in four patients (2%), for procalcitonin measurement in 54 patients (27%), and for lactate measurement in 94 patients (47%). Data missing in the ME
ARDS cohort for the presence of a solid tumor with metastasis and for liver failure in two patients (1%), and in all patients for particular variables, where indicated.
bAcute kidney injury defined by a $0.5 mg/dl increase in serum creatinine [17].
cBased on admitting physician report.
dmtDNA level represents NADH dehydrogenase 1 DNA level expressed as copies per microliter.
doi:10.1371/journal.pmed.1001577.t001
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hospital. The median follow-up time for the group that died in the
hospital was 5 d (interquartile range 1–54 d). In the ME ARDS
study, 40 patients (16%) died within 28 d of ICU admission. In the
ME ARDS study, the rate of death among MICU patients (i.e.,
medical or cardiac ICU patients, n=31 deaths, 20%) differed from
that among non-MICU patients (i.e., surgical, trauma, or
neurological ICU patients, n=9 deaths, 10%, p=0.03 for the
difference). A majority of plasma samples were drawn within 4 d
of ICU admission in both the BWH RoCI (n=186, 93%) and the
ME ARDS (n=194, 90%, data missing on 34 patients) studies.
mtDNA Level and Mortality
BWH RoCI. In the BWH RoCI cohort, mtDNA level was
higher in ICU patients who died within 28 d of MICU admission
than in those who did not (median 9,504 copies/ml versus 1,927
copies/ml, p=261028; Figure 2A), as well as in patients with
diagnoses commonly associated with mortality in the ICU such as
sepsis (Figure 2B) and ARDS (Figure 2C). For each log10-unit
increase in mtDNA level, patients had an increased odds of dying
within 28-d of MICU admission (odds ratio [OR] 1.9, 95% CI
1.5–2.4, p=261027). Patients with an mtDNA level $3,200
copies/ml had an increased odds of dying within 28 d of MICU
admission (Table 2) and an increased odds of dying in the hospital
(OR 8.4, 95% CI 3.7–19.2, p=461027). Of those who died within
28 d of MICU admission, 80% (n=48 of 60) had an mtDNA level
$3,200 copies/ml compared to 38% (n=53 or 140) of those who
did not die. In the BWH RoCI cohort, the odds of dying within
28 d of MICU admission was higher among those with an
mtDNA level $3,200 copies/ml when the level was obtained
,48 h after ICU admission (n=52, OR 23.0, 95% CI 4.4–120.0,
p=261024) compared to those with an mtDNA level $3,200
copies/ml that was obtained $48 h after ICU admission (n=148,
OR 4.4, 95% CI 1.9–9.8, p=461024); however, this difference
was of borderline statistical significance (mtDNA by ICU status
interaction p=0.08). The additional analysis of nuclear DNA level
and mtDNA level in different patient groups in the BWH RoCI
study is shown in Texts S5 and S6 in Supporting Information S1.
There was no evidence in the BWH RoCI cohort that the
association between mtDNA level and MICU mortality was
attenuated in models adjusted for clinical covariates, including
APACHE II score, sepsis, or ARDS (Table 2). There was no
statistical evidence that any of these variables significantly
modified the effect of mtDNA level on mortality.
While an elevated mtDNA level was associated with acute
kidney injury (OR 3.2, 95% CI 1.7–6.3, p=461024), the need for
mechanical ventilation (OR 2.7, 95% CI 1.5–4.8, p=761024), the
use of vasopressors (OR 3.6, 95% CI 1.9–6.6, p=661025), and an
underlying diagnosis of cancer (OR 1.8, 95% CI 1.0–3.1, p=0.05),
there was no significant association of elevated mtDNA with
physician report of either liver failure (p=0.65) or heart failure
(p=0.45). The association between an elevated mtDNA level and
28-d mortality remained significant in the BWH RoCI cohort
even after adjustment for additional variables including use of
vasopressors, need for mechanical ventilation, cancer, acute
kidney injury, or admitting physician impression of either heart
or liver failure (OR 9.5, 95% CI 3.5–25.6, p=361025; see Table
S3 in Supporting Information S1).
Binary classification analysis for elevated mtDNA levels and 28-
d MICU mortality are shown in Table 3.
Of the 200 patients from the BWH RoCI cohort, we were able
to obtain simultaneous measurements of procalcitonin in 146
(73%) and lactate in 106 (53%) patients. To determine whether the
association between mtDNA and 28-d mortality could be
explained by measures of procalcitonin or lactate, we tested each
of these biomarkers for association with mortality and then
assessed whether adjusting for either procalcitonin or lactate
attenuates the association between mtDNA and mortality. All
three biomarkers were significantly associated with 28-d mortality
(Table 4). mtDNA level remained significantly associated with 28-
d mortality even after adjusting for either procalcitonin or lactate.
In contrast, the associations between procalcitonin and lactate and
mortality were attenuated in models additionally adjusting for
mtDNA level (Table 4).
Of the 200 BWH RoCI patients, 96 (48%) remained in the ICU
for 7 d and had a repeat measurement of mtDNA. Mortality level
was lowest among patients with mtDNA levels ,3,200/ml copies
at both their initial blood draw and day 7 (0% mortality), highest
in those with levels $3,200/ml copies at both visits (39%
mortality), and intermediate for those with an elevated mtDNA
level at only one of the two time points (,12% mortality; see
Table 5).
Follow-up data were available on the patients in the BWH
RoCI study for periods ranging from 1 d to 3.5 y after admission
to the ICU. 54% (n=108) of the cohort died during follow-up.
Patients who had an mtDNA level $3,200 copies/ml had an
increased risk of death (hazard ratio 2.4, 95% CI 1.6–3.6,
p,161024; see Figure 3). There was no evidence that the effect of
mtDNA level on the risk of death was attenuated in adjusted
models (Text S7 in Supporting Information S1). mtDNA level was
associated with an increased risk of death even in analyses limited
to patients with sepsis (after adjusting for age, gender, race/
ethnicity, and APACHE II score, an mtDNA level$3,200 copies/
ml was associated with an increase in the risk of death, hazard ratio
3.0, 95% CI 1.5–6.3, p=0.003) or ARDS (after adjusting for age,
gender, race/ethnicity, and APACHE II score, an mtDNA level
$3,200 copies/ml was associated with a 2.3-fold increase in the
risk of death, hazard ratio 2.3, 95% CI 1.5–3.5, p=261024).
ME ARDS. Comparable to our findings in the BWH RoCI
cohort, mtDNA levels were higher in ME ARDS patients who
died within 28 d of ICU admission (median 7,457 copies/ml) than
in patients who did not (median 2,846 copies/ml, p=561026;
Figure 2A), and were higher in patients with sepsis (Figure 2B) or
ARDS (Figure 2C) than in patients without these conditions. Also
similarly to the BWH RoCI cohort, for each log10-unit increase in
mtDNA level, patients had an increased odds of dying within 28-d
of ICU admission (OR 1.6, 95% CI 1.2–2.0, p=961024), those
with an mtDNA level $3,200 copies/ml had an increased odds of
dying within 28 d of ICU admission (Table 2), and there was no
evidence that the association between mtDNA level and ICU
mortality was attenuated in models adjusted for covariates
(Table 2).
In contrast to the BWH RoCI study, the ME ARDS study
included ICU patients from non-medical ICUs (i.e., surgical,
trauma, and neurological ICUs). In stratified analyses, the
association between an elevated mtDNA level and 28-d mortality
was limited to MICU patients. Importantly, there was no evidence
for an association between mtDNA level and 28-d mortality in
non-MICU patients (mtDNA by ICU status interaction 0.03; see
Table 2).
mtDNA Level and 28-d Mortality Reclassification and
Prediction
BWH RoCI. To further assess the importance of mtDNA as
an ICU biomarker, we tested the ability of mtDNA level to
improve reclassification of patients in the BWH RoCI cohort. The
inclusion of mtDNA level $3,200 copies/ml resulted in a 79%
improvement in net reclassification when added to a clinical model
(including age, gender, race/ethnicity, APACHE II score, and
Mitochondrial DNA and Death in the ICU
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sepsis; see Table 4). The improvement in net reclassification
remained significant, albeit attenuated, when mtDNA level was
added to clinical models including known ICU biomarkers (e.g.,
procalcitonin or lactate; see Table 4). While measurement of
lactate levels improved the reclassification of patients when added
to a clinical model, measurement of procalcitonin did not (Table 4).
In contrast, measurement of lactate did not improve reclassifica-
tion when added to a clinical model that included mtDNA level
(NRI 4%, standard error [SE] 14%, p=0.80). Similarly, in the
BWH RoCI cohort there was evidence that an mtDNA level of
$3,200 copies/ml improved 28-d mortality prediction when added
to a model with clinical variables using c-statistics (the c-statistic
was 0.76, 95% CI 0.68–0.83, for a model including age, gender,
race/ethnicity, APACHE II score, and sepsis, which improved to
0.83, 95% CI 0.77–0.90, with the inclusion of mtDNA level,
p,0.001 for the comparison) (Figure 4A).
ME ARDS. Similar to our findings in the BWH RoCI cohort,
the addition of an elevated mtDNA level improved net reclassi-
fication of ICU patients when added to a clinical model in the ME
ARDS cohort (Table 4). The improvement in net reclassification
Figure 2. Cell-free mtDNA level in the plasma of ICU patients. Boxplots comparing measures of cell-free mtDNA level (mtDNA [NADH
dehydrogenase 1] expressed as copy number/ml of plasma) in the plasma of (A) patients who died within 28 d after ICU admission (red) versus those
who survived (gray), (B) patients with (green) versus without (gray) sepsis, and (C) patients with (blue) versus without (gray) ARDS in the BWH RoCI
(left) and ME ARDS (right) cohorts. mtDNA copy number in the plasma is presented as median value (black line), interquartile range (box), and 5th and
95th percentiles (whiskers). p-Values are noted in the figure for each cohort.
doi:10.1371/journal.pmed.1001577.g002
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in the ME ARDS cohort was due to the improvement in
reclassifying MICU patients (Table 4), as no significant improve-
ment was noted in non-MICU patients (NRI 4%, SE 16%,
p=0.82). Similarly, there was evidence that an mtDNA level of
$3,200 copies/ml improved 28-d mortality prediction when added
to a model with clinical variables using c-statistics (the c-statistic
was 0.85, 95% CI 0.79–0.92, for a model including age, gender,
and APACHE II score, which improved to 0.86, 95% CI 0.80–
0.92, with the inclusion of mtDNA level, p=0.02 for the
comparison) in the ME ARDS cohort (Figure 4B), although
improvement in prediction was limited to MICU patients (the c-
statistic was 0.87, 95% CI 0.81–0.93, for a model including age,
gender, and APACHE II score, which improved to 0.89, 95% CI
0.83–0.94, with the inclusion of mtDNA level, p=0.008 for the
comparison) (Figure 4C), as no significant improvement was noted
in non-MICU patients (the c-statistic was 0.82 regardless of the
inclusion of mtDNA level, p=0.97 for the comparison).
Additional analyses combining both cohorts are presented in
Text S8 and Table S4 in Supporting Information S1.
Discussion
Elevated levels of circulating cell-free mtDNA are associated
with ICU mortality, particularly among MICU patients, from
multiple cohorts. We demonstrate that mtDNA can improve risk
prediction beyond commonly measured biomarkers, such as
lactate, and combined measures of baseline characteristics and
underlying physiology (e.g., APACHE II score) among MICU
patients. In the BWH RoCI cohort, based primarily on the
strength of the association between elevated mtDNA level and 28-
day mortality, elevated mtDNA levels predicted an increased risk
of death that persisted over up to 3.5 y of follow-up.
Based on the data we present in this study, it is not possible to
determine whether the observed increased circulating cell-free
mtDNA levels were increased as the result of the severity of illness
alone, or whether mtDNA actively contributes to disease
pathogenesis in MICU patients [32–34]. Recent observations
[12] show that mtDNA contributes to activation of inflamma-
some, a large multimolecular complex that controls the proteo-
Table 2. Bivariate and multivariate analyses of association between elevated mtDNA levels and 28-d MICU mortality.
Model 28-d MICU Mortality
BWH RoCI
(n=200) ME ARDS
All Patients
(n=243)
MICU Patientsa
(n=152)
Non-MICU Patientsb
(n=91)
Unadjusted 6.6 (3.2–13.4)
361027
3.8 (1.7–8.3)
0.001
5.3 (2.0–14.0)
661024
1.7 (0.4–7.4)
0.46
Adjustedc 7.5 (3.6–15.8)
161027
4.2 (1.9–9.6)
661024
8.4 (2.9–24.2)
961025
1.5 (0.3–7.0)
0.58
Adjustedc+APACHE II score 5.6 (2.6–12.1)
161025
3.4 (1.4–8.4)
0.008
6.2 (1.9–20.4)
0.002
1.1 (0.2–5.6)
0.90
Adjustedc+sepsis 9.0 (3.9–20.7)
261027
3.1 (1.4–7.3)
0.008
6.0 (2.0–17.8)
0.001
1.1 (0.2–5.5)
0.92
Adjustedc+ARDS 6.9 (3.3–14.8)
561027
3.6 (1.2–10.8)
0.02
5.3 (1.6–17.5)
0.007
1.3 (0.3–6.1)
0.73
Data are given as OR (95% CI) followed by p-value. Elevated mtDNA level represents NADH dehydrogenase 1 DNA copy number of $3,200 copies/ml plasma.
aIncludes MICU and cardiac ICU patients.
bIncludes surgical ICU, trauma ICU, and neurological ICU patients.
cMultivariate models in both cohorts were adjusted for age, gender, and race/ethnicity, with additional adjustments where indicated.
doi:10.1371/journal.pmed.1001577.t002
Table 3. Elevated mtDNA levels and 28-d MICU mortality by group.
Statistical Test 28-d MICU Mortality
BWH RoCI
(n=200) ME ARDS
All Patients
(n=243)
MICU Patientsa
(n=152)
Non-MICU Patientsb
(n=91)
Sensitivity 80% 75% 81% 67%
Specificity 62% 52% 56% 46%
Positive predictive value 48% 24% 32% 12%
Negative predictive value 88% 92% 92% 93%
Elevated mtDNA level represents NADH dehydrogenase 1 DNA copy number of $3,200 copies/ml plasma.
aIncludes MICU and cardiac ICU patients.
bIncludes surgical ICU, trauma ICU, and neurological ICU patients.
doi:10.1371/journal.pmed.1001577.t003
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lytic enzyme caspase-1 [33,34]. Inflammasome activation is
exclusively responsible for caspase-1-mediated IL-1b and IL-18
maturation and secretion in immune cells [33,34], and circulating
IL-1b and IL-18 levels are known to be increased in critically ill
patients with both sepsis and ARDS [1,14,35]. These findings, in
conjunction with the findings presented in here, suggest that
circulating mtDNA could serve as a marker of death and,
independently, may represent an important pathogenic determi-
nant that contributes to an exaggerated systemic inflammatory
response [36].
Our data are consistent with prior studies demonstrating that
circulating cell-free mtDNA levels are elevated in critically ill
subpopulations including adults with community-acquired bacte-
rial meningitis [8], trauma [7], or sepsis in the emergency room
[37], and further implicates the mitochondria, both in terms of
genotyping (mtDNA haplogroups) [38] and now cell-free mtDNA
plasma measurement, as an important factor predicting survival.
In addition, our study demonstrates, to our knowledge for the first
time, that elevated mtDNA levels may be particularly important in
improving risk prediction in the MICU.
In addition to the evidence that elevated mtDNA levels are
associated with sepsis, ARDS, and mortality, an important and
unique aspect of our study is that we provide replicated evidence
that mtDNA level improves risk prediction in MICU patients.
Metrics of association and prediction should not be confused, as
only the latter suggest that a finding may have clinical applicability
as a test for an individual patient [39]. Although we present
statistical evidence that mtDNA level improves our ability to predict
death among MICU patients using both c-statistics and reclassifi-
cation methods, it is important to note that some studies suggest that
reclassification methods are more sensitive than c-statistics when
comparing the magnitude of predictive improvement [30,40].
Our study has a number of important limitations. First, although
we demonstrate that an elevated mtDNAmeasurement is associated
with ICU mortality among MICU patients from multiple cohorts,
there was no evidence for a similar association among non-medical
Table 4. Peripheral blood biomarkers and 28-d ICU mortality.
Association Prediction
BWH RoCI (n=200) BWH RoCI (n=200) ME ARDS
All Patients
(n=243)
MICU Patientsa
(n=152)
Model
OR (95% CI)
p-Value Model
NRI (SE)
p-Valueb
NRI (SE)
p-Valueb
NRI (SE)
p-Valueb
Elevated mtDNA levelc 6.6 (3.2–13.4)
361027
Elevated mtDNA levelc+clinical modeld 79% (14%)
,0.0001
28% (13%)
0.03
55% (20%)
0.007
Procalcitonin (mg/l) 1.02 (1.01–1.03)
0.004
Procalcitonin (mg/l)+clinical modeld 11% (9%)
0.25
— —
Lactate (mg/dl) 1.4 (1.1–1.7)
0.002
Lactate (mg/dl)+clinical modeld 36% (15%)
0.02
— —
Elevated mtDNA levelc+
procalcitonin (mg/l)e
6.6 (2.3–18.2)
561024
Elevated mtDNA levelc+clinical
modeld+procalcitonin (mg/l)
52% (15%)
661024
— —
Elevated mtDNA levelc+lactate
(mg/dl)f
7.0 (2.1–22.8)
0.001
Elevated mtDNA levelc+clinical
modeld+lactate (mg/dl)
36% (17%)
0.03
— —
aIncludes MICU and cardiac ICU patients.
bp-Value using risk categories in increments of 10% from 0%–100%. In all cases the NRI value refers to the addition of the noted biomarker to the clinical model
(including age, gender, race/ethnicity, APACHE II score, and sepsis) and additional biomarkers, where indicated.
cElevated mtDNA level represents NADH dehydrogenase 1 DNA copy number of $3,200 copies/ml plasma compared to those with ,3,200 copies/ml.
dClinical model includes age, gender, race/ethnicity, APACHE II score [20], and sepsis.
eThe effect of procalcitonin on the mortality is no longer significant after adjusting for an elevated mtDNA level (OR 1.01, 95% CI 0.99–1.02, p= 0.42).
fThe effect of lactate on the mortality is attenuated after adjusting for an elevated mtDNA level (OR 1.2, 95% CI 0.99–1.51, p= 0.05).
doi:10.1371/journal.pmed.1001577.t004
Table 5. Repeated measures of mtDNA and 28-d mortality in the BWH RoCI cohort.
Categories Based on Repeated mtDNA Measurement
Number (Percent)a Alive
at 28-d (n=74)
Number (Percent)a Who Died
after 28-d (n=22)
mtDNA level ,3,200 copies/ml on initial blood draw and day 7 10 (100%) 0 (0%)
mtDNA level $3,200 copies/ml on initial blood draw and ,3,200 copies/ml on day 7 7 (87.5%) 1 (12.5%)
mtDNA level ,3,200 copies/ml on initial blood draw and $3,200 copies/ml on day 7 30 (88%) 4 (12%)
mtDNA level $3,200 copies/ml on initial blood draw and day 7 27 (61%) 17 (39%)c
mtDNA level represents NADH dehydrogenase 1 DNA copy number.
aData missing for 104 (52%) of the BWH RoCI patients at day 7 of ICU admission. The mortality rate was higher among those missing data at day 7 of ICU admission
(37%, n= 38) than among those who had data at day 7 of ICU admission (23%, n=22, p for the comparison = 0.03).
cThere was a significant association between repeated measures of mtDNA and mortality among these BWH RoCI patients (Fisher’s exact test, p= 0.007).
doi:10.1371/journal.pmed.1001577.t005
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Figure 3. Survival of BWH RoCI MICU patients stratified by mtDNA level. Kaplan-Meier estimates of survival for patients who had plasma
mtDNA levels $3,200 copies/ml (n= 101) and ,3,200 copies/ml (n=99) in the BWH MICU. The middle black line indicates the Kaplan-Meier survival
curve for patients who had mtDNA ,3,200 copies/ml, with 95% confidence intervals (outer black lines and gray shading). The middle red line
indicates the Kaplan-Meier survival curve for patients who had mtDNA $3,200 copies/ml, with 95% confidence intervals (outer red lines and pink
shading). Survival in patients with mtDNA $3,200 copies/ml was significantly lower than in patients with mtDNA ,3,200 copies/ml (p-value noted in
the figure).
doi:10.1371/journal.pmed.1001577.g003
Figure 4. Receiver operating characteristic curves, mtDNA, and death in ICU patients. Comparisons of receiver operating characteristic
(ROC) curves for a clinical model (including age, gender, race/ethnicity, APACHE II score, and sepsis) (solid lines) and a clinical model with an mtDNA
level $3,200 copies/ml (dashed lines) to predict 28-d mortality in ICUs. (A) The area under the curve was 0.76 for a clinical model and was 0.83 for a
clinical model with an mtDNA level $3,200 copies/ml in the BWH RoCI cohort. (B) The area under the curve was 0.85 for a clinical model and was 0.86
for a clinical model with an mtDNA level $3,200 copies/ml in the ME ARDS cohort when all patients were included. (C) The area under the curve was
0.87 for a clinical model and was 0.89 for a clinical model with an mtDNA level $3,200 copies/ml in the subpopulation of ME ARDS MICU patients.
doi:10.1371/journal.pmed.1001577.g004
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(predominantly surgical) ICU patients. Although we cannot
definitively determine the reasons behind these differences within
the context of this study, we can’t rule out that subtle differences in
the timing of sample collection could have influenced the
associations within these two groups. In addition, these findings
suggest that mtDNA could be released from cells or tissue as the
result of surgery, and in this situation an elevated mtDNA level may
be unlikely to be associated with an increased risk of mortality. Of
note, although some studies demonstrate that patients who meet
criteria for systemic inflammatory response syndrome (SIRS) have
worse outcomes [41], this does not appear to hold among surgical
ICU patients, where the presence of systemic inflammatory
response syndrome is very common [42]. Second, some of the
comparisons between biomarkers in the BWH RoCI study are
limited because of missing data (e.g., lactate measurements). Third,
although our assessments of repeated measures of mtDNA suggest
that the trajectory of this measurement may be of clinical
importance, we urge caution in interpreting these results, as our
findings also demonstrate that the probability of being alive to have
had mtDNA remeasured was also dependent on the initial mtDNA
level. These findings support the idea that future studies of mtDNA
in MICU patients could benefit from repeated measurements,
including those prior to ICU presentation. Fourth, although
fungemia was rare in both the BWH RoCI and ME ARDS cohorts
(Text S4 in Supporting Information S1), it is worth noting that fungi
have mtDNA that may cross-react with human mtDNA primers
[10,43]. Finally, it is important to note that our analyses reflect that
the mtDNA level adds to, rather than replaces, information gleaned
from commonly measured physiologic parameters and biomarkers.
In conclusion, we show that mtDNA level in plasma is associated
with mortality in MICU patients. Elevated mtDNA level adds to
mortality risk prediction in the ICU, and represents an advance over
currently used ICU biomarkers and the APACHE score. Given the
relative ease and rapidity (the entire process currently takes,6 h) of
mtDNA measurement, circulating cell-free mtDNA could be a
valuable addition to assessment of MICU patients, and points the
way to the possibility of new diagnostic and/or therapeutic
approaches for patients with critical illness.
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Editors’ Summary
Background. Intensive care units (ICUs, also known as
critical care units) are specialist hospital wards that provide
care for people with life-threatening injuries and illnesses. In
the US alone, more than 5 million people are admitted to
ICUs every year. Different types of ICUs treat different types
of problems. Medical ICUs treat patients who, for example,
have been poisoned or who have a serious infection such as
sepsis (blood poisoning) or severe pneumonia (inflammation
of the lungs); trauma ICUs treat patients who have sustained
a major injury; cardiac ICUs treat patients who have heart
problems; and surgical ICUs treat complications arising from
operations. Patients admitted to ICUs require constant
medical attention and support from a team of specially
trained nurses and physicians to prevent organ injury and to
keep their bodies functioning. Monitors, intravenous tubes
(to supply essential fluids, nutrients, and drugs), breathing
machines, catheters (to drain urine), and other equipment
also help to keep ICU patients alive.
Why Was This Study Done? Although many patients
admitted to ICUs recover, others do not. ICU specialists use
scoring systems (algorithms) based on clinical signs and
physiological measurements to predict their patients’ likely
outcomes. For example, the APACHE II scoring system uses
information on heart and breathing rates, temperature,
levels of salts in the blood, and other signs and physiological
measurements collected during the first 24 hours in the ICU
to predict the patient’s risk of death. Existing scoring systems
are not perfect, however, and ‘‘biomarkers’’ (molecules in
bodily fluids that provide information about a disease state)
are needed to improve risk prediction for ICU patients. Here,
the researchers investigate whether levels of circulating cell-
free mitochondrial DNA (mtDNA) are associated with ICU
deaths and whether these levels can be used as a biomarker
to improve risk prediction in ICU patients. Mitochondria are
cellular structures that produce energy. Levels of mtDNA in
the plasma (the liquid part of blood) increase in response to
trauma and infection. Moreover, mtDNA activates molecular
processes that lead to inflammation and organ injury.
What Did the Researchers Do and Find? The researchers
measured mtDNA levels in the plasma of patients enrolled in
two prospective observational cohort studies that monitored
the outcomes of ICU patients. In the Brigham and Women’s
Hospital Registry of Critical Illness study, blood was taken
from 200 patients within 24 hours of admission into the
hospital’s medical ICU. In the Molecular Epidemiology of
Acute Respiratory Distress Syndrome study (acute respiratory
distress syndrome is a life-threatening inflammatory reaction
to lung damage or infection), blood was taken from 243
patients within 48 hours of admission into medical and non-
medical ICUs at two other US hospitals. Patients admitted to
medical ICUs with a raised mtDNA level (3,200 or more
copies of a specific mitochondrial gene per microliter of
plasma) had a 7- to 8-fold increased risk of dying within 28
days of admission compared to patients with mtDNA levels
of less than 3,200 copies/ml plasma. There was no evidence
of an association between raised mtDNA levels and death
among patients admitted to non-medical ICUs. The addition
of an elevated mtDNA level to a clinical model for risk
prediction that included the APACHE II score and biomarkers
that are already used to predict ICU outcomes improved the
net reclassification index (an indicator of the improvement in
risk prediction algorithms offered by new biomarkers) of 28-
day mortality among medical ICU patients in both studies.
What Do These Findings Mean? These findings indicate
that raised mtDNA plasma levels are associated with death in
medical ICUs and show that, among patients in medical ICUs,
measurement of mtDNA plasma levels can improve the
prediction of the risk of death from the APACHE II scoring
system, even when commonly measured biomarkers are
taken into account. These findings do not indicate whether
circulating cell-free mtDNA increased because of the
underlying severity of illness or whether mtDNA actively
contributes to the disease process in medical ICU patients.
Moreover, they do not provide any evidence that raised
mtDNA levels are associated with an increased risk of death
among non-medical (mainly surgical) ICU patients. These
findings need to be confirmed in additional patients, but
given the relative ease and rapidity of mtDNA measurement,
the determination of circulating cell-free mtDNA levels could
be a valuable addition to the assessment of patients
admitted to medical ICUs.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001577.
N The UK National Health Service Choices website provides
information about intensive care
N The Society of Critical Care Medicine provides information
for professionals, families, and patients about all aspects of
intensive care
N MedlinePlus provides links to other resources about
intensive care (in English and Spanish)
N The UK charity ICUsteps supports patients and their
families through recovery from critical illness; its booklet
‘‘Intensive Care: A Guide for Patients and Families’’ is
available in English and ten other languages; its website
includes patient experiences and relative experiences of
treatment in ICUs
N Wikipedia has a page on ICU scoring systems (note that
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
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